Aurobindo Pharma receives USFDA nod for Quinapril tablets

Drug maker Aurobindo Pharma Ltd today said the company has received final approval from the US health regulator to manufacture and market Quinapril tablets in the American market.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead master your money Realasset
moneycontrol.com

Home » News » Business

Apr 30, 2013, 04.43 PM | Source: PTI

Aurobindo Pharma receives USFDA nod for Quinapril tablets

Drug maker Aurobindo Pharma Ltd today said the company has received final approval from the US health regulator to manufacture and market Quinapril tablets in the American market.

Like this story, share it with millions of investors on M3

Aurobindo Pharma receives USFDA nod for Quinapril tablets

Drug maker Aurobindo Pharma Ltd today said the company has received final approval from the US health regulator to manufacture and market Quinapril tablets in the American market.

Post Your Comments

Share Cancel

Aurobindo Pharma receives USFDA nod for Quinapril tablets
Drug maker Aurobindo Pharma Ltd today said the company has received final approval from the US health regulator to manufacture and market Quinapril tablets in the American market.

The company has received the approval from the US Food and Drug Administration (USFDA) to manufacture the drug, which is indicated for the treatment of hypertension and falls under the cardiovascular (CVS) therapeutic category, in strengths of 5mg, 10mg, 20mg and 40mg (ANDA 202725), it said in a release.

Also read: Aurobindo Pharma gets USFDA approval for Cefadroxil oral suspension

The market size of the product is estimated to be USD 49 million for the 12 months ended September 2012, according to IMS, it said. The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad, it said. Aurobindo now has a total of 188 ANDA approvals (161 final approvals including 4 from Aurolife Pharma LLC and 27 tentative approvals) from USFDA, the release added. Shares of Aurobindo were quoting at Rs 187.70 apiece, down 2.24 per cent, in the late afternoon trade on the BSE.

Aurobindo Pharm stock price

On May 31, 2016, at 09:54 hrs Aurobindo Pharma was quoting at Rs 764.10, up Rs 9.65, or 1.28 percent. The 52-week high of the share was Rs 891.50 and the 52-week low was Rs 582.00.


The company's trailing 12-month (TTM) EPS was at Rs 26.47 per share as per the quarter ended December 2015. The stock's price-to-earnings (P/E) ratio was 28.87. The latest book value of the company is Rs 94.48 per share. At current value, the price-to-book value of the company is 8.09.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Aurobindo Pharma receives USFDA nod for Quinapril tablets

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login